Form 4: Sangamo Therapeutics: CEO Acquires Stock Options

Sangamo Therapeutics, Inc. reports that President, CEO, and Director Sandy Macrae was granted stock options for 2.5 million shares.

Summary

• Sandy Macrae, President, CEO, and Director of Sangamo Therapeutics, Inc., was granted stock options on April 1, 2026.
• The options are for 2,500,000 shares of common stock.
• The exercise price for these options is $0.2601 per share.
• The options have an expiration date of March 31, 2036.
• Vesting of the options occurs in stages: one-quarter vests on the first anniversary of the grant date, with the remainder vesting in 24 successive equal monthly installments thereafter.
• Vesting is contingent upon Macrae's continued service with the company and is subject to acceleration as provided in the 2018 Equity Incentive Plan (EIP).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating executive confidence and long-term alignment, though it does not represent new financial performance data.

Positives

• The CEO's acquisition of stock options signals confidence in the company's future prospects.
• The long expiration date of the options (March 31, 2036) suggests a long-term commitment and alignment with company growth.
• The structured vesting schedule encourages continued service and performance.

Risks

• The vesting of options is subject to the Reporting Person's Continuous Service, meaning departure from the company would result in forfeiture of unvested options.
• The value of the options is tied to the future performance of Sangamo Therapeutics' stock price, which is subject to market volatility and company-specific risks.

Future Outlook

The grant of stock options to the CEO with a long-term vesting schedule suggests management's positive outlook on the company's future performance and growth potential.

Management Comments

• One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Industry Context

StockSavvy.ai notes that the granting of significant stock options to senior executives is a common practice in the biotechnology and pharmaceutical sectors to incentivize long-term performance and align executive interests with shareholder value, especially for companies focused on research and development.

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with long-term shareholder value creation, potentially leading to increased focus on company growth and profitability.
• Employees: The CEO's commitment, as evidenced by the option grant, may positively influence employee morale and retention.
• Management: Reinforces the long-term commitment of key leadership.

Next Steps

• Continued service by Sandy Macrae to meet vesting requirements.
• Monitoring of stock performance to determine the future value of the options.

Key Dates

Recommendation

This filing is an insider transaction report detailing stock option grants to the CEO. While it suggests executive confidence, it does not provide new financial performance data or strategic shifts that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate pending further operational or financial updates.

Keywords

Sangamo Therapeutics, SGMO, Form 4, Stock Options, Executive Compensation, Insider Trading, SEC Filing, Equity Incentive Plan, Sandy Macrae